Goodnough L T, Scott M G, Monk T G
Department of Pathology, Washington University School of Medicine, St. Louis, MO 63110-1093, USA.
Clin Orthop Relat Res. 1998 Dec(357):89-100. doi: 10.1097/00003086-199812000-00013.
Prospects for safe and effective blood substitutes are promising, based on clinical trial results of soluble hemoglobin solutions and emulsion of perfluorocarbins. Advantages of blood substitutes include sterilization of viral and bacterial contaminants, room temperature storage, a long shelf life, and absence of ABO and other red cell antigens. Projected arenas for their use include not only military applications but also trauma medicine and elective surgical settings, coupled with acute normovolemic hemodilution. Applications of perfluorocarbons are limited by the need for 100% FIO2. A significant challenge facing development of hemoglobin solutions is their effect on vascular tone through smooth muscle constriction. Development of second or third generation hemoglobin solutions may be necessary so that hemoglobin solutions more closely mimic cellular hemoglobin's nitric oxide binding properties. Optimizing O2 delivery to ischemic tissues and organs may lead to regulatory approval of these agents in this setting before their approval as blood substitutes.
基于可溶性血红蛋白溶液和全氟碳化物乳剂的临床试验结果,安全有效的血液替代品前景广阔。血液替代品的优点包括对病毒和细菌污染物进行灭菌、室温储存、保质期长以及不存在ABO和其他红细胞抗原。预计其使用领域不仅包括军事应用,还包括创伤医学和择期手术环境,以及急性等容血液稀释。全氟碳化物的应用受到需要100% 吸入氧浓度的限制。血红蛋白溶液开发面临的一个重大挑战是其通过平滑肌收缩对血管张力的影响。可能需要开发第二代或第三代血红蛋白溶液,以便血红蛋白溶液更紧密地模拟细胞血红蛋白的一氧化氮结合特性。在这些药物被批准作为血液替代品之前,优化向缺血组织和器官的氧气输送可能会使其在这种情况下获得监管批准。